ArticleBioinformatics (Oxford, England)2026
Prevalence aware feature selection improves biomarker identification in microbiome studies.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
motivationIdentifying robust microbial biomarkers is crucial for disease diagnosis and prediction, elucidation of biological mechanisms, and development of targeted therapies. Machine learning-based approaches, particularly the random forest model, have been widely used for biomarker identification during sample stratification. However, those biomarkers often vary considerably for the same disease, limiting their practical applicability. A robust framework for reliable biomarker identification in microbiome research is needed. To address this gap, we proposed a prevalence-aware feature selection framework (ParSlet) that incorporates a universal scaling relationship between taxon prevalence and selection frequency.
resultsWe first identified a universal exponential scaling law linking the probability of a taxon being consistently recognized as a biomarker versus its prevalence. Then, we integrated this scaling law with taxa prevalence into the biomarker identification using random forest. We systematically evaluated this approach in both simulated microbiome datasets and real-world microbiome datasets and compared it with existing methods, finding that our integrated approach generally improved feature stability and reproducibility of biomarker identification. In colorectal cancer (CRC) datasets, our method robustly identified well-established microbial biomarkers such as Ruminococcus, Clostridium_XVIII, and Faecalibacterium. Integrating a prevalence-based scaling adjustment into feature importance enhances the stability of microbiome biomarker identification. This approach holds promise for enabling more reliable disease diagnostics, uncovering generalizable microbial signatures across cohorts, and guiding the development of targeted microbiome-based interventions. AVAILABILITY AND IMPLEMENTATION: ParSlet is available at https://github.com/KelabatOSU/Feature_selection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.